NewsRoom Articles - Page 3 of 219

FridayOct 17, 2025 10:00 am

Virtual Brain Tumors Could Transform How Cancer is Treated

Brain tumors, such as glioblastoma, are very hard to treat and even surgery isn’t sufficient to fully remove the tumor since tiny particles of cancerous cells remain and proliferate within a short time. However, ongoing work at Cedars-Sinai promises to transform brain cancer treatment by creating a digital twin of a patient’s tumor and then predicting how the cancer will grow and how it could respond to different therapies. In this way, treatment teams can better personalize treatments for individual patients. At the heart of this work is Kristin Swanson, PhD, who is engaged in pioneering work that combines mathematics…

ThursdayOct 16, 2025 10:00 am

Researchers Urge Canadians to Donate Toenails, for Science

A new study that is being planned by scientists at the University of Calgary, Canada, is looking to receive up to 10,000 toenail samples from volunteers around the country. The reason for this seemingly odd request is to study how to accurately measure how much radon someone has been exposed to and link this exposure to their risk of developing lung cancer. The drivers of the development of lung cancer have been quite an enigma to the scientific community. While smoking has been identified to be a leading cause of the disease, a notable fraction of lung cancer patients don’t…

ThursdayOct 16, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV ketamine formulation. The filing follows FDA approval of the company’s Suitability Petition to remove benzethonium chloride (“BZT”), a preservative linked to neurotoxicity. In parallel, NRx is advancing NRX-100, another preservative-free ketamine formulation under a New Drug Application (“NDA”) for suicidal ideation in depression, including bipolar depression. NRX-100 holds Fast Track Designation and may qualify for the FDA’s National Priority Voucher Program. The company also continues work on NRX-101, a Breakthrough Therapy for suicidal bipolar depression. CEO Dr. Jonathan Javitt recently discussed new pipeline developments and…

WednesdayOct 15, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Izotropic recently published a piece that explores the way AI is redefining breast imaging and the way the innovative IzoView system was designed for the future The company’s 3D breast CT platform helps tackle one of the major concerns of cancer screening: radiation exposure in CT imaging With its trade-secret reconstruction algorithm, AI-native design, and fair price model, IzoView strategically places Izotropic to dominate the future of breast imaging technology These latest updates further highlight Izotropic’s mission: to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility Izotropic (CSE: IZO) (OTCQB: IZOZF) is changing how breast cancer imaging is…

TuesdayOct 14, 2025 10:00 am

New Report Highlights Concerning Trends in the US Health Care System

There is general agreement that the U.S. health care system has issues, but there isn’t consensus on what exactly needs to be done to fix those issues. A new report published by Trilliant Health, an economic analysis company, points out some notable trends that should be given the attention they deserve by health care system stakeholders. The authors indicate in the report that by 2033, the share of GDP going into health care costs will climb to 20.3%. On the surface, this may look like increasing amounts of resources are going to be channeled into health care and this would…

MondayOct 13, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products. The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring…

FridayOct 10, 2025 11:15 am

Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development

Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies. Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey. Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design. The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern’s new CNS cancer drug, can benefit from these AI-driven insights. In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of…

FridayOct 10, 2025 10:00 am

How You Can Support Your Loved One Undergoing Cancer Treatment

Having a loved one diagnosed with cancer can be a very difficult time for that person and those within their immediate circle. It is often difficult to know how to support the patient during their treatment and some people make mistakes in their bid to be supportive. We discuss some suggestions that could be helpful if a loved one is undergoing cancer treatment. For starters, it is good to focus on what you are good at and offer help along those lines. Don’t try to be or do everything in your bid to help. For example, if you come from…

ThursdayOct 09, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

The expansion of Soligenix’s European Medical Advisory Board underscores the company's commitment to delivering innovative treatment options to European patients. HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options. Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial…

ThursdayOct 09, 2025 10:00 am

Scientists Stunned Upon Discovering Glioblastoma Erodes Skull Tissue

For long, treatment approaches to glioblastoma, the deadliest form of brain cancer, have assumed that the disease is localized. However, a recent study has found that GBM erodes the skulls of its victims and this could partially explain why the current therapies have had dismal success rates against the tumors. For their study, the team analyzed scans of the skulls of mice afflicted by two types of glioblastoma. They found that the skulls were thinner than they should be. On examining scans of humans with GBM, they found altered skull thickness, especially in the areas where bones fused. The study…